European shares of AstraZeneca fell 9% after its late-stage clinical trial of Wainua, a drug for treating nervous system disorders, failed to meet expectations.

2026-07-09

European shares of AstraZeneca fell 9% after its late-stage clinical trial of Wainua, a drug for treating nervous system disorders, failed to meet expectations.